National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Descovy® (F/TAF) is licensed in combination with other antiretroviral agents (ARVs) for the treatment of adults and adolescents (≥12 years; body weight ≥35 kg) infected with human immunodeficiency virus (HIV) type 1.


Rapid Review

Commenced Completed Outcome
26/04/2016 26/04/2016 Full Pharmacoeconomic Evaluation Recommended at the Submitted Price.

The HSE has approved reimbursement following confidential price negotiations.